Afternoon and good morning, ladies and gentlemen. Thank you for joining us today. My name is Amy Wakeham, ResMed's Vice President of Corporate Communications and Investor Relations. Welcome to ResMed's 2020 Annual Stockholders Meeting. Due to the challenges of having meetings in person during this time, we are conducting this year's annual meeting in a virtual-only format. During the meeting, the online polls will be open for voting by anyone who has registered on the portal and wishes to vote online with respect to any of the three proposals. Instructions for online registration can be found in your proxy materials. While the meeting is virtual only, we still welcome questions from our stockholders. We'll answer questions from stockholders who have registered via the virtual meeting portal. If you are registered on the portal, you will have opportunities to ask questions related to the specific proposals when those are taken up.
If you have difficulty registering, please email us at investorrelations@resmed.com. We will close the polls at the end of the discussion of our three proposals. We'll also have a general Q&A session at the portion of the meeting where other questions can be asked. I'd like to call your attention to the rules of conduct for the meeting. They can be found via the link located at the bottom of the virtual annual meeting screen. I will now turn the meeting over to our host for the afternoon, Peter Farrell.
Thank you, Amy. Well, good evening, good afternoon, good morning. Ladies and gentlemen, welcome to ResMed's Annual General Meeting. I am Peter Farrell, Non-Executive Chairman of the ResMed Board of Directors. Before we begin, I would like to take a moment to introduce our directors and officers who are on the line for the virtual meeting today. Let me start with the candidates for election. Karen Drexler, who's a member of our Compensation Committee, is standing for re-election, and Mick Farrell, Chief Executive Officer, is also standing for re-election. In addition to Karen and Mick, ResMed has six other members of the Board of Directors who are continuing in office, but who are not currently up for re-election. I am Chair of the Board, not up for re-election. Carol Burt, who's Chair of our Audit and Compliance Oversight Committee, as well as a member of our Nominating and Governance Committee.
Jan De Witte, who's a member of our Audit and Compliance Oversight Committee. Harjit Gill, a member of our Compensation Committee. Richard Sulpizio, the Chair of our Compensation Committee and a member of our Nominating and Governance Committee. Finally, Ronald Taylor, Chair of our Nominating and Governance Committee, who is also a member of our Audit and Compliance Oversight Committee and is also our Lead Director. Ron, Mick, and I will be on the speakers line today. Now let me introduce the three other ResMed officers present with us. Rob Douglas, President and Chief Operating Officer. David Pendarvis, Chief Administrative Officer, Global General Counsel, and Secretary. Brett Sandercock, our Chief Financial Officer. Ryan Evans and Chris Finlay from KPMG, ResMed's independent registered public accounting firm, are available on the speakers line.
For the administration of this meeting, David Pendarvis will act as Secretary of the meeting, and Jim Alden from American Election Services, LLC, will act as Inspector of Elections. The 2020 Annual Meeting of Stockholders of ResMed Inc. will now come to order. We will begin with the formal part of the meeting, which consists of items one through three on the agenda, circulated in the notice of meeting and proxy statement. After the formal part of the meeting, Mick will give a brief presentation and then open the virtual meeting to general questions. We will announce preliminary results of the voting before the end of the meeting after all items have been voted upon. I'll now ask David Pendarvis to report on the mailing of the notice of meeting and notice and access to proxy materials, and advise if there is a quorum present so that we may begin.
David?
Mr. Chairman, the notice of internet availability of proxy materials for the meeting was mailed on or about October the 6th of 2020 to all stockholders of record as of September 22nd. Represented at this meeting in person, online, or by proxy are over 118,017,583 shares of common stock, and that represents approximately 81.44% of the shares that are outstanding and entitled to vote.
Thank you, David. A quorum is present, and we may now carry out the official business of the meeting. The time is whatever the current time is. It's 2:05 PM. The polls are now open for each matter to be voted on today, as Amy described at the outset. The first item of business is the election of two directors. The board of directors has nominated Karen Drexler and Mick Farrell to serve as directors of ResMed until the 2021 annual meeting. Because no other persons have been properly nominated in accordance with the bylaws, the nominations are now closed. Is there any discussion with respect to the nomination for directors?
Peter, no questions have been submitted.
Thank you. Thanks, Amy. The second item of business is to ratify the appointment of KPMG LLP as ResMed's independent registered public accounting firm for the fiscal year ending June 30, 2021. Is there any discussion about KPMG's appointment?
Peter, no questions have been submitted.
Thank you, Amy. The third and final item of business is to approve on an advisory basis the compensation paid to our named executive officers as disclosed in the proxy statement. Is there any discussion on this topic?
No questions have been submitted here either.
Well, thank you, Amy. These are the only proposals for today's meeting. The time is 2:07 PM on November 19th. The polls are now closed for the meeting. The Inspector of Elections has completed preliminary vote tabulation. Will the Secretary please report on those voting results?
The preliminary results are as follows. Karen Drexler and Mick Farrell are both elected as directors, both receiving over 109 million shares voting for them. The appointment of KPMG LLP as our independent registered public accounting firm is ratified with over 113 million shares voted to approve, and the proposal to approve on an advisory basis the compensation paid to our named executive officers, as disclosed in the proxy statement, is also approved with over 101 million shares voting in favor. The final results and the voting details will be reported in a filing that we will make in the next few days with the U.S. Securities and Exchange Commission, and that filing will be available on the SEC's website.
Great. Well, thank you, Dave. This concludes the formal portion of the meeting. I declare the meeting adjourned. Now that the formal business has been transacted, Mick will take a few moments to update you on ResMed's progress this past year and some of our plans for future growth.
Fantastic. Thank you, Mr. Chairman. Let's pull up the slides on the webcast for those looking at that live. The first slide here is just a presentation of our disclaimers around forward-looking statements, please read over that at your leisure. I'll go through to the main slide here, which is titled ResMed 2025: A Patient Centric, Digitally Enabled Strategy. Look, this is sort of a summary of multiple years of work and many thousands of spreadsheets and PowerPoints. What we're trying to do here is capture our five-year strategy on one page. As Mark Twain said, "Sorry I wrote you such a long letter because I didn't have time to write you a short one." We've tried to write a short letter here.
This page summarizes our goal that over the next five years, we are going to impact the lives of 250 million people, helping them live happier, healthier, and higher quality lives. Helping them sleep better, helping them breathe better, and helping them have high-quality life well away from a hospital. Look, our purpose is that our growth focus is to do that in our core market of sleep apnea. It's where our business was founded by the gentleman to my left here, 31 years ago this year, to strive to help the 936 million people worldwide who suffocate every night. We've added on to that, our core market of sleep apnea, a growth focus in chronic obstructive pulmonary disease, where there are over 380 million people worldwide who have lung dysfunction and on a chronic basis such that it's chronic obstructive pulmonary disease.
I actually think that's an underestimate from the World Health Organization and that it's over 400 million. We'll watch those prevalence data get updated the same way we updated our sleep apnea data. Of course, we've moved into the asthma market in the last two years with the acquisition of Propeller, which is over 340 million people worldwide. You add those three markets together, sleep apnea, 900+ million, COPD, 300 million to 400 million, and asthma over 300 million. We're talking about over 1.5 billion people, one in every five persons on this planet, have a chronic respiratory disease that ResMed can treat. That's what we're aiming for. You could argue that the 250 million lives maybe isn't ambitious enough with that.
In addition, our growth focus includes software as a service. That's an area that's now material in over 10% of our business, we break it out every quarter. That's our business of helping people in out-of-hospital care, whether it's in home medical equipment, which is our primary area with Brightree, or also in skilled nursing facilities, home health, hospice, life plan communities, senior living, private care, private duty home care, and beyond. Moving on to the next slide. We talked about having that patient-centric strategy and going after 250 million people worldwide, helping them sleep better, breathe better, and live better lives through digital health. What does that mean? That means digitizing everything we do, creating digital transformation for every market we're in.
We've spent the last seven years reinventing the sleep apnea market around digital health, and we are doing the same right now in COPD, and we will do it in asthma and software as a service for out-of-hospital care. Right the moment, we have over seven billion nights of medical sleep and COPD and asthma data in the cloud. We have over 14 million patients that doctors can access in our AirView system, and we have over three million patients themselves. If you think of them as the ultimate customer, that person who suffocates, who has difficulty breathing, three million of them have signed up for our application, our app called myAir, and we're able to engage with them on a daily basis.
By the way, as CEO, I'm also a patient, and I'm also a user of our system and an active user of our digital health platform, and it's good, but it's getting better every day and every sprint. Moving on to the next slide. How does this all tie together? Well, big data is one thing, saying we've got seven billion nights of data, but what do you do with that data? How do you turn those data into actionable information that actually influences a patient outcome, influences a business outcome, or influences the operations of us, our supply chain from our suppliers or our customers? We have spent the last seven years building this capability, and we have incredible results. We have lowered the labor cost of setting a patient up on sleep apnea therapy by 59%.
59% reduction in labor costs for our customers, home medical equipment company. We moved the average adherence rate from the peer-reviewed literature. If you go and look at it's 50%-60% adherence rates out there in the peer-reviewed literature. We're able to achieve over 87% adherence in published data with Kaiser Permanente. We've replicated that over many, many accounts that haven't been published. That's better business outcomes, better patient outcomes. We've actually applied these capabilities of artificial intelligence and machine learning throughout our system to engage with patients, to engage with doctors, and we'll be working on our own supply chain. I'm looking at our chief operating officer right now to say that we can use AI ML on our own. Physician heal thyself. Moving to the next slide, my third last slide here. This isn't our first quarter of success.
We had a great quarter here in Q1. We've been doing this for, well, since 1995, when we went public 26 years ago, and certainly now 21 years on the New York Stock Exchange and then co-listed on ASX. Our five-year, total shareholder return is over 270%. Our three-year total shareholder return's over 157%. One year is over 59%. That five quarter rolling, if you think about it, that's 20 quarters in a row of having very good success over that time. Look, clearly there's been a once in every century impact to the global healthcare system here with COVID. Turning to that response and what we did in that crisis, we made over 150,000 ventilators from January 1 to June 30, and provided them to many of the over 140 countries worldwide that we serve.
It was incredible what we were able to do. Our team gets motivated by certainly growing the business and taking care of people. In an emergency like that, where many people, many companies couldn't do anything, ResMed was able to pivot and take what was a small single-digit percentage of its business in ventilation and triple, and actually quintuple the production of our Astral ventilator and get them around the world and have those ventilators on bedside tables that truly were part of saving lives. As we move forward, we think that sort of tailwinds of the ventilator sales and that emergency is gone. We have flattened the curve of hospitalizations. We've flattened the curve of ICU and ventilator needs. Now we're back to growing in our core business.
We expect sequential quarter-on-quarter growth of our sleep apnea, COPD, and asthma patient flow as they come back. Germany doing particularly well, 85%-90% of patient flow there. Here in the U.S., around 70% of patient flow, and on average in Asia, somewhere in that sort of 60%-80% of patient flow. If we move to the last slide. You take the last 12 months of what ResMed's done, $3 billion in revenue, a very strong total shareholder return. For us ResMedians, the thing that matters is that we delivered over 15 million sleep apnea, COPD, and asthma medical devices and full mask systems.
We helped over 100 million people in out-of-hospital software, whether it's a digital health platform reminding them to take their COPD or asthma medication, or reminding them to get a new mask, or just helping them live a better life outside the hospital. We're gonna grow that at double digits every year from now through 2025, and we are going to impact over 250 million lives in 2025. That's it for my presentation. I'll now open up for any questions, Amy, that we might have coming through either the portal or through the email, and myself, the chairman, lead director, Rob, and Dave will be available to answer any of those, and Brett.
Great. Thanks, Mick. Far, we have no questions via the online meeting or in investor relations email.
Well, great. Well, look, feel free to keep the conversation going. Many of you follow us on our quarterly conference calls, and you can hear about what we're doing every 90 days there. There are many of these conferences that are now going virtual in the banking world, and so you don't have to travel to London or New York to attend them. I look forward to seeing many of you there. Amy, I'll hand back to you to close out the meeting.
Great. Thanks, Mick. That concludes our meeting. Thank you all for coming today. You may disconnect.